Saudi Food and Drug Authority Suspends The Authorisation of Rosiglitazone (Avandia®)
1. The risk of using rosiglitazone outweighs its benefit especially risks of cardiovascular events including myocardial infarction and congestive heart failure in addition to increased risk of fractures.
2. Safer alternatives could be used for treatment of diabetes mellitus are available in Saudi Arabia.
Based on the review it was recommended to suspended rosiglitazone containing product.
For further information, please visit:
http://www.sfda.gov.sa
Avandia in the News:
- (Reuters) - Saudi Arabia has suspended GlaxoSmithKline's (GSK.L) diabetes drug Avandia for six months, arguing that potential heart risks outweigh its benefits. Read more...
- (Dow Jones) Saudi Arabia has suspended GlaxoSmithKline PLC's (GSK) diabetes drug Avandia for six months, saying the product's heart risks outweigh its benefits, but the U.K.-based drug maker said its stands by the controversial drug. Read more...
Most Read News
- Abbott to Acquire Action Pharma's Investigational Compound, AP214
- GlaxoSmithKline and Yale University establish drug discovery collaboration
- AstraZeneca and The Medicines Company announce global collaboration in acute ischaemic heart disease
- Serious safety concerns around unlicensed ocular bevacizumab use versus Lucentis
- Novartis updates US label on Gilenya® following discussions with the FDA
- Bristol-Myers Squibb delivers a solid first quarter
- AstraZeneca to acquire Ardea Biosciences for $1 billion
Company Profiles and News
Showcase your Company Profile / News
Pharmaceutical Companies
News in Pictures
Be on top of World Pharma News!
Advertise with us - Download World Pharma News' Media Pack Read more
Abbott Launches New Psoriasisanswers.com Web site
August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more
AstraZeneca Headquarters, London
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more
Site Roche Basel
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more
Gehry building, Novartis headquarters in Basel, Switzerland
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more
GSK Corporate HQ
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more
Sanofi-aventis Group head office
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more
Boehringer Ingelheim Center, Ingelheim, Germany
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more
Novo Nordisk's corporate headquarters in Bagsværd, Denmark
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more
Sponsored Video
Business & Industry News
- Roche will report new data on important progress for people with advanced cancers at ASCO 2012
- Amgen's BiTE® antibody blinatumomab (AMG 103) achieved high rate of complete response
- Merck total revenues increase 3.2% to € 2.6 billion
- Pfizer provides topline results from Phase 3 study of Torisel®
- GlaxoSmithKline to fully acquire Cellzome for £61 million
- Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India
- Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership
Research & Development News
- Biomarker predicts response to cancer treatment
- In drug-approval race, US FDA ahead of Canada, Europe
- Blood pressure drugs don't protect against colorectal cancer
- Vitamin K2: New hope for Parkinson's patients?
- H1N1 discovery paves way for universal flu vaccine
- Some HDL, or 'good' cholesterol, may not protect against heart disease
- Potential to revive abandoned cancer drug by nanoparticle drug delivery
Conferences & Events News
- 3rd Mastering HR Summit 2012
- ePatient / Health 2.0 - A Key Factor for New and Innovative Business Models for the Life Sciences Industry
- Global E-Health Forum - Hamburg 2011
- Health 2.0 Europe: Over 35 Speakers from 15 Countries Already Confirmed
- 2nd Mastering HR Summit 2011
- Health 2.0 Europe 2011 - Registration is Now Open
- Global E-Health Forum: Designing Personalized Healthcare